Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)



42 start-ups through to Catapult 2022-23 semifinals

We are excited to today announce the 42 promising start-ups that will go through to the semifinals of EIT Health Catapult 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. Many participants of the competition have gone on to excel in their respective fields.

Read More »

Wefight annouces its partnership with Kiplin

We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!

Read More »
Domain Therapeutics

Domain Therapeutics raises $42m Series A financing

Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.

Read More »

Latest Insights

Vik Asthma received the #EnnovaHealth21 prize by Diario Médico and Correo Farmacéutico in the category #PatientEmpowerment

One year after its launch in Spain, Vik Asthma received the #EnnovaHealth21 prize by Diario Médico and Correo Farmacéutico in the category #PatientEmpowerment. As our teams continue to grow, we are proud to see the impact that #Vik Asthma has had in patients’ lives, providing support and real-time answers. This couldn’t have been possible without the institutional support of AstraZeneca and local association Fenaer Pacientes.